SUPPORTING INFECTIOUS DISEASE RESEARCH

# Escherichia coli, Strain NCDC U14-41

## Catalog No. NR-102

(Derived from ATCC<sup>®</sup> 23501<sup>™</sup>)

## For research only. Not for human use.

Contributor:

ATCC®

## **Product Description:**

Bacteria Classification: Enterobacteriaceae, Escherichia Species: Escherichia coli (E. coli) Strain: NCDC U14-41

Serotype: O3:K2a,2b(L):H2

- <u>Original Source</u>:<sup>1</sup> Isolated in 1943 by Dr. F. Kauffmann from human urine
- <u>Comment:</u> *E. coli*, strain NCDC U14-41 was deposited at ATCC<sup>®</sup> in 1967 by Dr. William H. Ewing, Bacteriology Section, National Communicable Disease Center, Atlanta, Georgia.

*E. coli* is a gram-negative rod-shaped bacterium which occurs singly or in pairs. It is a major facultative inhabitant of the large intestine.

*E. coli* strain NCDC U14-41 is an enteroaggregative *E. coli* (EAEC). PCR probes have been developed to identify the presence of aggregative adherence pattern associated plasmid (pAA) and the virulence marker *aggR*, which are commonly associated with EAEC.

The presence of pAA has been confirmed by PCR amplification of the marker sequences CVD432 and *aggR* from extracted nucleic acid.

## **Material Provided:**

Each vial contains approximately 0.5 mL of bacterial culture in 0.5X Tryptic Soy Broth supplemented with 10% glycerol.

### Packaging/Storage:

NR-102 was packaged aseptically, in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

## **Growth Condition:**

Media: Tryptic Soy Broth or equivalent Tryptic Soy Agar or equivalent Incubation: Temperature: 37°C Atmosphere: Aerobic

#### Propagation:

- 1. Keep vial frozen until ready for use, then thaw.
- 2. Transfer the entire thawed aliquot into a single tube of Tryptic Soy Broth.
- 3. Use several drops of the suspension to inoculate a Tryptic Soy Agar slant and/or plate.
- 4. Incubate the tubes and plate at 37°C for 24 hours.

#### Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: *Escherichia coli*, Strain NCDC U14-41, NR-102."

### **Biosafety Level: 2**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <u>Biosafety in</u> <u>Microbiological and Biomedical Laboratories</u>. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see <u>www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm</u>.

### **Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at <u>www.beiresources.org</u>.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC<sup>®</sup> nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC<sup>®</sup> nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal.  $ATCC^{\circledast}$  and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government,  $ATCC^{\circledast}$ , their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

## Use Restrictions:

This material is distributed for internal research, noncommercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as **b**|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

### References:

- 1. <u>Acta Pathol. Microbiol. Scand.</u> 20 (1943): 21–44.
- Brenner, D. J., et al. "Atypical Biogroups of *Escherichia coli* Found in Clinical Specimens and Description of *Escherichia hermannii* sp. nov." <u>J. Clin. Microbiol.</u> 15 (1982): 703–713. PubMed: 7040466.
- Schmidt, H., et al. "Development of PCR for Screening of Enteroaggregative *Escherichia coli*." <u>J. Clin. Microbiol.</u> 33 (1995): 701–705. PubMed: 7751380.
- Tsai, C. C., S. Y. Chen, and H. Y. Tsen. "Screening the Enteroaggregative *Escherichia coli* Activity and Detection of the *aggA*, *aafA*, *and astA* Genes with Novel PCR Primers for the *Escherichia coli* Isolates from Diarrhea Cases in Taiwan." <u>Diagn. Microbiol. Infect. Dis.</u> 46 (2003): 159–165. PubMed: 12867090.
- Ogata, K., et al. "Prevalence of *Escherichia coli* Possessing the *eaeA* Gene of Enteropathogenic *E. coli* (EPEC) or the *aggR* Gene of Enteroaggregative *E. coli* (EAggEC) in Traveler's Diarrhea Diagnosed in Those Returning to Tama, Tokyo from Other Asian Countries." <u>Jpn. J. Infect. Dis.</u> 55 (2002): 14–18. PubMed: 11971156.
- Moon, J. Y., J. H. Park, and Y. B. Kim. "Molecular Epidemiological Characteristics of Virulence Factors on Enteroaggregative *E. coli*." <u>FEMS Microbiol. Lett.</u> 253 (2005): 215–220. PubMed: 16257141.

ATCC<sup>®</sup> is a trademark of the American Type Culture Collection.

